Evidence map›Paper›PMID 27420051›Full record

ReviewInternational journal of molecular sciences2016

Cell Fusion in the War on Cancer: A Perspective on the Inception of Malignancy.

Jeffrey L Platt, Xiaofeng Zhou, Adam R Lefferts, Marilia Cascalho

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Recent Advances in Studies of Skin Color and Skin Cancer.The Yale journal of biology and medicine · 2020
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jeffrey L PlattDepartments of Surgery and of Microbiology & Immunology, University of Michigan, A520B Medical Sciences Research Building I, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-5656, USA. plattjl@umich.edu.
Xiaofeng ZhouDepartments of Surgery and of Microbiology & Immunology, University of Michigan, A520B Medical Sciences Research Building I, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-5656, USA. xiazhou@med.umich.edu.
Adam R LeffertsDepartments of Surgery and of Microbiology & Immunology, University of Michigan, A520B Medical Sciences Research Building I, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-5656, USA. aleffert@umich.edu.
Marilia CascalhoDepartments of Surgery and of Microbiology & Immunology, University of Michigan, A520B Medical Sciences Research Building I, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-5656, USA. marilia@umich.edu.
University of Michigan · US

Funding

Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Hepatocyte xenografts for treatment of acute liver failureR01AI122369 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FOX, IRA J., PLATT, JEFFREY L · 2016 to 2020
$5.0M
Xenogeneic Natural Antibody Targets-Structure/FunctionR37HL052297 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PLATT, JEFFREY L · 2001 to 2010
$3.9M
Enhancing resistance to enteric pathogensR21AI117561 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2015 to 2016
$426k
XENOGENEIC NATURAL ANTIBODY TARGETS--STRUCTURE/FUNCTIONR01HL052297 · NHLBI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI PLATT, JEFFREY L · 1993 to 2000
$319k
NCATS NIH HHS UL1 TR000433NHLBI NIH HHS R01 HL052297NHLBI NIH HHS R37 HL052297NIAID NIH HHS R01 AI122369NIAID NIH HHS R21 AI117561
6 · The paper itself

Abstract

Cell fusion occurs in development and in physiology and rarely in those settings is it associated with malignancy. However, deliberate fusion of cells and possibly untoward fusion of cells not suitably poised can eventuate in aneuploidy, DNA damage and malignant transformation. How often cell fusion may initiate malignancy is unknown. However, cell fusion could explain the high frequency of cancers in tissues with low underlying rates of cell proliferation and mutation. On the other hand, cell fusion might also engage innate and adaptive immune surveillance, thus helping to eliminate or retard malignancies. Here we consider whether and how cell fusion might weigh on the overall burden of cancer in modern societies.

Indexed as

Cell FusionCell Transformation, NeoplasticDNA DamageHumansImmune SystemNeoplasmsaneuploidycancercancer progressioncell fusionDNA damageimmune surveillancemalignant transformationmitosismutationoncogenesis

Identifiers

PMID27420051
PMCPMC4964493
OpenAlexW2474943755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.